BioLineRx (BLRX) Interest & Investment Income (2013 - 2025)
BioLineRx (BLRX) posted Interest & Investment Income of $303000.0 for Q4 2025, down 19.63% on a QoQ basis from $377000.0 in Q3 2025, and down 10.09% year-over-year from $337000.0 in Q4 2024.
BioLineRx (BLRX) has 13 years of Interest & Investment Income data on file, last reported at $303000.0 in Q4 2025.
- In Q4 2025, Interest & Investment Income fell 10.09% year-over-year to $303000.0; the TTM figure through Dec 2025 stood at $1.5 million (down 21.75% YoY), while the FY2025 annual figure was $1.5 million, down 21.75% from the prior year.
- Interest & Investment Income retreated to $303000.0 in Q4 2025, from $377000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $779000.0 in Q4 2023 and bottomed at $52000.0 in Q3 2021.
- A 5-year average of $332800.0 and a median of $324500.0 in 2023 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2021 — Interest & Investment Income surged 1081.82% — and 2024, when it slumped 56.74%.
- Year by year, Interest & Investment Income stood at $260000.0 in 2021, then surged by 68.46% to $438000.0 in 2022, then surged by 77.85% to $779000.0 in 2023, then slumped by 56.74% to $337000.0 in 2024, then slipped by 10.09% to $303000.0 in 2025.
- The last three Interest & Investment Income figures came in at $303000.0 (Q4 2025), $377000.0 (Q3 2025), and $490000.0 (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 26.60 Mn |
| 10 | BioLineRx | 9.32 Bn | 9.30 Bn | 154,000.00 | 303,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 303,000.00 |
| Sep 30, 2025 | 377,000.00 |
| Jun 30, 2025 | 490,000.00 |
| Mar 31, 2025 | 294,000.00 |
| Dec 31, 2024 | 337,000.00 |
| Sep 30, 2024 | 434,000.00 |
| Jun 30, 2024 | 535,000.00 |
| Mar 31, 2024 | 565,000.00 |
| Dec 31, 2023 | 779,000.00 |
| Sep 30, 2023 | 312,000.00 |
| Jun 30, 2023 | 440,000.00 |
| Mar 31, 2023 | 537,000.00 |
| Dec 31, 2022 | 438,000.00 |
| Sep 30, 2022 | 109,000.00 |
| Jun 30, 2022 | 80,000.00 |
| Mar 31, 2022 | 67,000.00 |
| Dec 31, 2021 | 260,000.00 |
| Sep 30, 2021 | 52,000.00 |
| Jun 30, 2021 | 130,000.00 |
| Mar 31, 2021 | 117,000.00 |
| Dec 31, 2020 | 22,000.00 |
| Sep 30, 2020 | 39,000.00 |
| Jun 30, 2020 | 35,000.00 |
| Mar 31, 2020 | 140,000.00 |
| Dec 31, 2019 | 149,000.00 |
| Sep 30, 2019 | 247,000.00 |
| Jun 30, 2019 | 171,000.00 |
| Mar 31, 2019 | 210,000.00 |
| Dec 31, 2018 | 185,000.00 |
| Sep 30, 2018 | 154,000.00 |
| Jun 30, 2018 | 287,000.00 |
| Mar 31, 2018 | 175,000.00 |
| Dec 31, 2017 | 255,000.00 |
| Sep 30, 2017 | 153,000.00 |
| Jun 30, 2017 | 304,000.00 |
| Mar 31, 2017 | 457,000.00 |
| Dec 31, 2016 | 77,000.00 |
| Sep 30, 2016 | 172,000.00 |
| Jun 30, 2016 | 88,000.00 |
| Mar 31, 2016 | 143,000.00 |
| Dec 31, 2015 | 94,000.00 |
| Sep 30, 2015 | 85,000.00 |
| Jun 30, 2015 | 205,000.00 |
| Mar 31, 2015 | 73,000.00 |
| Dec 31, 2014 | 1.35 Mn |
| Sep 30, 2014 | 1.99 Mn |
| Jun 30, 2014 | 35,000.00 |
| Mar 31, 2014 | 355,000.00 |
| Dec 31, 2013 | 18,000.00 |
| Sep 30, 2013 | 142,000.00 |
| Jun 30, 2013 | 365,000.00 |
| Mar 31, 2013 | 182,000.00 |